DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Withdrawn Grounds of Rejection
The rejection of claim 1 under 35 U.S.C. 112(b), is withdrawn due to the claim amendments.
Claim Objections
Claim 1 is objected to because of the following informalities: the structure of the compound of Formula I is blurry, especially at the piperazine ring, wherein the various X-substituents are very blurry. Appropriate correction is required.
New Grounds of Rejection
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or non- obviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1, 95-98, 101, 103, 105, 107-110, 113, 115, and 117 are rejected under 35 U.S.C. 103 as being unpatentable over Suzie Ribeiro WO 2015/087283 A1 (IDS, 07/21/2026) in view of Adam Morgan WO 2014/028595 A1, Harbeson et al., US PG-PUB 2010/0221221 A1.
Ribeiro (page 1, line 7-9) teaches solid pharmaceutical dosage forms comprising the drug
substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-
phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. Ribeiro (page 1, line 20-22) teaches the compound of Formula I is a protein kinase inhibitor and is useful in the treatment of proliferative diseases mediated by protein kinases. Ribeiro (page 1, line 20-22) further teaches the compound inhibits FGFR1, FGFR2, FGFR3, FGFR4, which is comparable to the claimed non-deuterated compound infigratinib (specification, [0041]). Ribeiro,
PNG
media_image1.png
106
372
media_image1.png
Greyscale
however, does not explicitly teach compound of Formula I is deuterated.
Morgan (page 3, [9]; page 32, claim 16; page 3, [9]) teaches ponatinib (AP-24534), a protein kinase inhibitor and demonstrates potential as an inhibitor to VEGFR and FGFR. Morgan (page 2, [6]-[7]) teaches that replacement of hydrogen atoms with deuterium may improve the metabolic stability of a compound by slowing metabolic degradation and reducing the formation of undesirable metabolites. Morgan (page 2, [6]-[7]) further added that such improvement can enhance ADME properties and may improve efficacy, safety, and tolerability of a compound.
PNG
media_image2.png
612
1436
media_image2.png
Greyscale
For example, Morgan (page 30, claim 1; page 31, claim 13) discloses compounds of Formula I, wherein one or more hydrogen atoms on the piperazine moiety are replaced with deuterium atoms. This suggests that the deuterated piperazine moiety is critical for the compound’s inhibitory potency. This approach is further supported by Harbeson (abstract; [0003] and [0008] page 1, [0002] and [0008]-[0010]; pages 19, [0213]) who teaches the same concept of deuterating the piperazine moiety of imatinib, a protein kinase inhibitor.
PNG
media_image3.png
525
591
media_image3.png
Greyscale
Given that both Morgan and Harbeson disclose protein kinase inhibitors containing piperazine moieties and teach deuterium substitution as a means of modifying ADME and metabolic properties. Therefore, it would be obvious to a person of ordinary skill in the art (POSITA) to recognize that deuteration of piperazine moiety as a recognized strategy for improving metabolic, stability, efficacy, safety, and tolerability. Therefore, a POSITA would have been motivated to replace one or more hydrogen atoms on the piperazine moiety of Ribeiro’s compound with deuterium in view of Morgan and Harbeson’s disclosure with reasonable expectation that the such modification would enable the compound to not only retain its kinase inhibitory activity but also to improve its ADME and metabolic characteristics.
Subject Matter Free of the Art of Record
The subject matter of claims 99-100, 102, 104, 106, 111-112, 114, 116, and 118 is free of the art of record. The closest prior art is Suzie Ribeiro WO 2015/087283 A1, in view of Adam Morgan WO 2014/028595 A1 and Harbeson et al., US PG-PUB 2010/0221221 A1. Although the combined teachings of Ribeiro in view of Morgan and Harbeson teach deuteration of the piperazine moiety of compound, 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, the prior art fails to teach or suggest deuteration of the ethyl substituent on the piperazine group. Therefore, there is no motivation for a POSITA to modify the teaching of prior art to arrive at the claimed compound. The instant application is not allowable until the 103 rejection is overcome.
Claims 99-100, 102, 104, 106, 111-112, 114, 116, and 118 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Conclusion
Claims 1, 95-98, 101, 103, 105, 107-110, 113, 115, and 117 are rejected. Claims 1, 99-100, 102, 104, 106, 111-112, 114, 116, and 118 are objected. No claims are allowed.
Applicant's submission of an information disclosure statement under 37 CFR 1.97(c) with the timing fee set forth in 37 CFR 1.17(p) on July 21, 2026 prompted the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 609.04(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PIERRE PAUL ELENISTE whose telephone number is (571)270-0589. The examiner can normally be reached Monday - Friday 8:00 am - 5:00 pm (EST).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JAMES H ALSTRUM-ACEVEDO can be reached at (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/P.P.E./Examiner, Art Unit 1622
/JAMES H ALSTRUM-ACEVEDO/
Supervisory Patent Examiner, Art Unit 1622